Zentalis Lawsuit Submission Form | Class Action Lawsuit List

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Owned

Purchase Date

Estimated Loss

Class Action Lawsuit List does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

Zentalis announced on June 18, 2024, that “the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC).”

Following this news, Zentalis’s stock price fell over 50% on June 18, 2024.

Active Cases

Ticker Symbol	Company Name	Join Deadline	Join
NSSC	Napco Security Technologies, Inc.	June 24, 2025	Join
NSSC	Napco Security Technologies, Inc.	June 24, 2025	Join
CODI	Compass Group Diversified Holdings, LLC	July 08, 2025	Join
IOVA	Iovance Biotherapeutics, Inc.	July 14, 2025	Join
OGN	Organon & Co.	July 22, 2025	Join

Zentalis Pharmaceuticals, Inc.

ZNTL

Zentalis Pharmaceuticals, Inc. Form

Active Cases